AgingResearch.NewsJoin free

RyCarma Therapeutics

CompanyUnited States

RyCarma Therapeutics develops one asset, in phase 2 (surlorian in autosomal dominant RYR1-Related myopathy). Mostly small molecule acting on RYR1; based in the United States.

1
Asset
Furthest stage
Phase 2
1
Trial
0
Signals

Pipeline

1

  • surlorian

    RYR1 channel stabilizer (calstabin/RyR stabilizer) preventing pathological calcium leak

    Phase 2, Small molecule, RYR1, autosomal dominant RYR1-Related myopathy

Full company profiles: pipeline, trials, funding and people.

See Pro

In the full profile

  • Evidence behind the mechanisms1
  • Trials1
  • Signals1

Intelligence